bioRxivImmunology
Structural basis for SARS-CoV-2 Nucleocapsid protein recognition by single-domain antibodies
Abstract
The COVID-19 pandemic, caused by the coronavirus SARS-CoV-2, is the most severe public health event of the twenty-first century. While effective vaccines against SARS-CoV-2 have been developed, there remains an urgent need for diagnostics to quickly and accurately detect infections. Antigen tests, particularly those that detect the abundant SARS-CoV-2 Nucleocapsid protein, are a proven method for detecting active SARS-CoV-2 infections. Here we report high-resolution crystal structures of three llama-derived single-domain antibodies that bind the SARS-CoV-2 Nucleocapsid protein with high affinity. Each antibody recognizes a specific folded domain of the protein, with two antibodies recognizing the N-terminal RNA binding domain and one recognizing the C-terminal dimerization domain. The two antibodies that recognize the RNA binding domain affect both RNA binding affinity and RNA-mediated phase separation of the Nucleocapsid protein. All three antibodies recognize highly-conserved surfaces on the Nucleocapsid protein, suggesting that they could be used to develop affordable diagnostic tests to detect all circulating SARS-CoV-2 variants.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Single-Domain SARS-CoV-2 S1 and RBD Antibodies Isolated from Immunized Llama Effectively Bind Targets of the Wuhan, UK, and South African Strains in vitro
- Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites
Sisi Kang, Mei Yang, … Shoudeng Chen·Acta Pharmaceutica Sinica BPeer-reviewed·Apr 20, 2020
- Rigid monoclonal antibodies improve detection of SARS-CoV-2 nucleocapsid protein
C. D. Hodge, D. J. Rosenberg, … M. Hammel·bioRxiv·Jan 13, 2021
- Development of SARS-CoV-2 Nucleocapsid Specific Monoclonal Antibodies
J. S. Terry, L. B. Anderson, … B. J. Geiss·bioRxiv·Sep 3, 2020
- Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity Nanobody.
Guillermo Valenzuela, Ronald Jara, … Alejandro Rojas‐Fernández·Scientific ReportsPeer-reviewed·Feb 8, 2021
- Characterization of SARS-CoV-2 N protein reveals multiple functional consequences of the C-terminal domain
C. Wu, A. J. Qavi, … D. W. Leung·bioRxiv·Nov 30, 2020